Cardiovascular Risk Management of Diabetes and SGLT2 Inhibitors

Did you know that every 10 seconds, one person dies from diabetes related complications such as heart disease, stroke, eye or kidney complications?

Featuring a lecture and discussion from Professor Masayuki Yoshida from Tokyo Medical and Dental University, this video highlights the important topic of cardiovascular risk management of patients with diabetes and explores the controversy around diabetes management and the prevention of cardiovascular disease.

It discusses the efficacy, mechanisms, benefits and outcomes of patients treated with the Sodium Glucose Contransporter-2 (SGLT2) Inhibitor, the DPP-4 inhibitor and Empagliflozin to control glucose re-absorption, using data from clinical trials such as the EMPA-REG OUTCOME trial.

Diabetologists
Endocrinologists
Consultant cardiologists
Cardiologists in training
General physicians
GPs
SpRs

Professor Masayuki Yoshida is from the University (TMDU) School of Medicine in Tokyo and completed a residency in Internal Medicine and Cardiology at TMDU hospital.

He completed his post-doctoral research fellowship at Department of Pathology, Harvard Medical School. His scientific theme included pathophysiology of vascular endothelium during atherosclerosis and inflammation. He discovered a novel signal transduction pathway of E-selectin, an adhesion molecule inducibly expressed on the surface of endothelial cells upon leukocyte adhesion. After returning to TMDU School of Medicine in 1996, he was appointed as an instructor in Molecular Medicine and then promoted to an Associate Professor in Medical Biochemistry.

In 2006, he became a professor and was tasked with managing a new research center for life science and bioethics (BERC) where he is responsible for ethical management of both clinical and basic research. During BERC’s first 5 years, it held several international symposiums to directly connect researchers and scientists in the field of research ethics and guidelines. The Center’s hands-on methods have helped researchers at TMDU significantly improve the quality of research protocols in TMDU. From 2010, Prof. Yoshida has led BERC as Director and further expands his commitment to create an environment to conduct good medical research.

Source: http://www.tmd.ac.jp/TMDU-e/isc/isp2011/speakers/yoshida.html

Professor Koji Hasegawa holds the following positions:

Director for the Division of Translational Research, Kyoto Medical Center and
Leader, Cardiovascular Clinical Research Network, National Hospital Organization
Visiting Professor, University of Shizuoka
President-elect, International Society of Cardiovascular Pharmacotherapy

His areas of interest and research focus on Risk factor control, smoking cessation, obesity and heart failure.

This webinar is to inform and educate interventional cardiologists and cardiac surgeons on:

diabetes care in terms of preventing cardiovascular events.
characteristics on SGLT2 inhibitors and their proper use.

EMPA-REG OUTCOME N Engl J Med 2015; 373:2117-2128　November 26, 2015
DOI: 10.1056/NEJMoa1504720